Novartis Ag (NVS) Total Non-Current Liabilities (2009 - 2026)

Novartis Ag has reported Total Non-Current Liabilities for 18 years, with the latest figure at $48.3 billion in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 57.83% year-over-year to $48.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $48.3 billion (up 57.83% YoY) and the FY2025 annual result came in at $37.1 billion, up 26.15% from the prior year.
• Total Non-Current Liabilities advanced to $48.3 billion in Q2 2026 per NVS's latest filing, from $100.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $48.3 billion in Q2 2026 and troughed at $100.0 million in Q1 2026.
• A 5-year average of $26.3 billion and a median of $29.4 billion in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities retreated 15.87% in 2023, then jumped 57.83% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $29.4 billion in 2022, then dropped by 8.75% to $26.8 billion in 2023, then grew by 9.79% to $29.4 billion in 2024, then advanced by 26.15% to $37.1 billion in 2025, then surged by 30.22% to $48.3 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $48.3 billion, $100.0 million, and $37.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.